Vice President, Commercial Services

I’ve spent more than 25 years in healthcare, and what I’ve learned is that while great science is a necessary foundation, it doesn’t automatically lead to market success. Someone has to connect those dots.

At Facet, I’m focused on integrating market thinking earlier in the product development process. Regulatory strategy and market value strategy aren’t two separate conversations but rather a collaborative, interactive dialogue that occurs throughout the entire product lifecycle. The companies that figure that out early are the ones that reach patients faster.

My career has taken me from building consumer marketing strategies for household names like Tylenol and Motrin at Johnson & Johnson, to leading immunology demand generation for REMICADE across rheumatology, gastroenterology, and dermatology, to serving as the sole commercial voice at a small PE-backed startup, OptiNose, where I helped close a $100M+ licensing deal with Avanir Pharmaceuticals. In between, I spent time at Wyeth/Pfizer generating the customer insight behind PRISTIQ — which hit #1 in pharma brand awareness and remained the driving force for the brand’s consumer initiatives for years after launch.

For the last decade, I’ve been doing what I love most through my consulting firm AirTight Strategies: helping emerging biotech and pharma companies figure out where their product fits in the market, how to position themselves for launch, and how to translate scientific differentiation into something that actually drives physician and patient demand. I’ve worked across numerous therapeutic areas, including rare diseases, oncology, immunology, neurology, and ophthalmology, with companies such as Merck, Novo Nordisk, AstraZeneca, Aurinia, BMS, and Alcon.